Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Urinary Incontinence-Pipeline Review, H1 2015

Urinary Incontinence-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Urinary Incontinence-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Urinary Incontinence-Pipeline Review, H1 2015', provides an overview of the Urinary Incontinence's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Urinary Incontinence, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Urinary Incontinence and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Urinary Incontinence

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Urinary Incontinence and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Urinary Incontinence products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Urinary Incontinence pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Urinary Incontinence

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Urinary Incontinence pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Urinary Incontinence Overview 8

Therapeutics Development 9

Pipeline Products for Urinary Incontinence-Overview 9

Pipeline Products for Urinary Incontinence-Comparative Analysis 10

Urinary Incontinence-Therapeutics under Development by Companies 11

Urinary Incontinence-Therapeutics under Investigation by Universities/Institutes 12

Urinary Incontinence-Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Urinary Incontinence-Products under Development by Companies 16

Urinary Incontinence-Products under Investigation by Universities/Institutes 17

Urinary Incontinence-Companies Involved in Therapeutics Development 18

Allergan, Inc. 18

Astellas Pharma Inc. 19

Beech Tree Labs, Inc. 20

Cook MyoSite Incorporated 21

Evotec AG 22

FemmePharma Global Healthcare, Inc. 23

Innovacell Biotechnologie AG 24

Recordati S.p.A. 25

TheraVida, Inc. 26

Urinary Incontinence-Therapeutics Assessment 27

Assessment by Monotherapy Products 27

Assessment by Combination Products 28

Assessment by Target 29

Assessment by Mechanism of Action 31

Assessment by Route of Administration 33

Assessment by Molecule Type 35

Drug Profiles 37

(mirabegron + solifenacin succinate)-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

(tolterodine + pilocarpine)-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

BTL-ui-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Cell Therapy for Urinary Incontinence-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

ICES-13-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

oxybutynin hydrochloride-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Prof-003-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

REC-1819-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

senrebotase-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Small Molecule to Antagonize P2X3 and P2X2/3 for Inflammatory Pain, Neuropathic Pain and Urinary Incontinence-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Stem Cell Therapy for CAD, Urinary Incontinence and Fecal Incontinence-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

THVD-202-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Urinary Incontinence-Recent Pipeline Updates 51

Urinary Incontinence-Dormant Projects 54

Urinary Incontinence-Discontinued Products 57

Urinary Incontinence-Product Development Milestones 59

Featured News & Press Releases 59

Jul 03, 2013: Impax Laboratories Confirms Patent Challenge Relating to Generic TOVIAZ 4 mg and 8 mg 59

Jan 03, 2013: TheraVida Announces Positive Top-line Phase II Results For Tolenix In Patients With Overactive Bladder And Urge Urinary Incontinence 59

Nov 06, 2012: Beech Tree Labs Completes Phase IIa Urinary Incontinence Clinical Trial Using UISH001 60

Mar 15, 2012: Innovacell To Present Phase IIb Trial Results Of ICES13 At MedTech Investing Europe Conference 60

Dec 05, 2011: Pfizer's Toviaz Shows Positive Top-Line Primary Endpoint Result In Study Of Overactive Bladder In Vulnerable Elderly Patients 61

Nov 08, 2011: Pfizer Announces Positive Top-Line Primary Endpoint Results Of Toviaz In Overactive Bladder Including Nocturnal Urinary Urgency 61

Aug 30, 2011: Innovacell passes a further milestone 62

May 16, 2011: TheraVida Initiates Phase II Trial Of THVD-201 For Overactive Bladder And Urinary Incontinence 63

Apr 13, 2011: Beech Tree Labs Initiates Urinary Incontinence Trial 63

Mar 22, 2011: TheraVida Announces Positive Results From Phase I Trial Of THVD-201 64

Appendix 65

Methodology 65

Coverage 65

Secondary Research 65

Primary Research 65

Expert Panel Validation 65

Contact Us 65

Disclaimer 66

List of Tables

Number of Products under Development for Urinary Incontinence, H1 2015 9

Number of Products under Development for Urinary Incontinence-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Number of Products under Investigation by Universities/Institutes, H1 2015 12

Comparative Analysis by Late Stage Development, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Development, H1 2015 15

Products under Development by Companies, H1 2015 16

Products under Investigation by Universities/Institutes, H1 2015 17

Urinary Incontinence-Pipeline by Allergan, Inc., H1 2015 18

Urinary Incontinence-Pipeline by Astellas Pharma Inc., H1 2015 19

Urinary Incontinence-Pipeline by Beech Tree Labs, Inc., H1 2015 20

Urinary Incontinence-Pipeline by Cook MyoSite Incorporated, H1 2015 21

Urinary Incontinence-Pipeline by Evotec AG, H1 2015 22

Urinary Incontinence-Pipeline by FemmePharma Global Healthcare, Inc., H1 2015 23

Urinary Incontinence-Pipeline by Innovacell Biotechnologie AG, H1 2015 24

Urinary Incontinence-Pipeline by Recordati S.p.A., H1 2015 25

Urinary Incontinence-Pipeline by TheraVida, Inc., H1 2015 26

Assessment by Monotherapy Products, H1 2015 27

Assessment by Combination Products, H1 2015 28

Number of Products by Stage and Target, H1 2015 30

Number of Products by Stage and Mechanism of Action, H1 2015 32

Number of Products by Stage and Route of Administration, H1 2015 34

Number of Products by Stage and Molecule Type, H1 2015 36

Urinary Incontinence Therapeutics-Recent Pipeline Updates, H1 2015 51

Urinary Incontinence-Dormant Projects, H1 2015 54

Urinary Incontinence-Dormant Projects (Contd..1), H1 2015 55

Urinary Incontinence-Dormant Projects (Contd..2), H1 2015 56

Urinary Incontinence-Discontinued Products, H1 2015 57

Urinary Incontinence-Discontinued Products (Contd..1), H1 2015 58

List of Figures

Number of Products under Development for Urinary Incontinence, H1 2015 9

Number of Products under Development for Urinary Incontinence-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 14

Assessment by Monotherapy Products, H1 2015 27

Assessment by Combination Products, H1 2015 28

Number of Products by Top 10 Targets, H1 2015 29

Number of Products by Stage and Top 10 Targets, H1 2015 30

Number of Products by Top 10 Mechanism of Actions, H1 2015 31

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 32

Number of Products by Top 10 Routes of Administration, H1 2015 33

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 34

Number of Products by Top 10 Molecule Types, H1 2015 35

Number of Products by Stage and Top 10 Molecule Types, H1 2015 36

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Allergan, Inc.

Astellas Pharma Inc.

Beech Tree Labs, Inc.

Cook MyoSite Incorporated

Evotec AG

FemmePharma Global Healthcare, Inc.

Innovacell Biotechnologie AG

Recordati S.p.A.

TheraVida, Inc.

Urinary Incontinence Therapeutic Products under Development, Key Players in Urinary Incontinence Therapeutics, Urinary Incontinence Pipeline Overview, Urinary Incontinence Pipeline, Urinary Incontinence Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com